Frequent and long-term exposure to hyperglycemia (i.e., high blood glucose) increases the risk of chronic complications such as neuropathy, nephropathy, and cardiovascular disease. Current technologies like continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) primarily model specific aspects of glycemic control-like hypoglycemia prediction or insulin delivery. Similarly, most digital twin approaches in diabetes management simulate only physiological processes. These systems lack the ability to offer alternative treatment scenarios that support proactive behavioral interventions. To address this, we propose GlyTwin, a novel digital twin framework that uses counterfactual explanations to simulate optimal treatments for glucose regulation. Our approach helps patients and caregivers modify behaviors like carbohydrate intake and insulin dosing to avoid abnormal glucose events. GlyTwin generates behavioral treatment suggestions that proactively prevent hyperglycemia by recommending small adjustments to daily choices, reducing both frequency and duration of these events. Additionally, it incorporates stakeholder preferences into the intervention design, making recommendations patient-centric and tailored. We evaluate GlyTwin on AZT1D, a newly constructed dataset with longitudinal data from 21 type 1 diabetes (T1D) patients on automated insulin delivery systems over 26 days. Results show GlyTwin outperforms state-of-the-art counterfactual methods, generating 76.6% valid and 86% effective interventions. These findings demonstrate the promise of counterfactual-driven digital twins in delivering personalized healthcare.

Postprandial hyperglycemia, marked by the blood glucose level exceeding the normal range after meals, is a critical indicator of progression toward type 2 diabetes in prediabetic and healthy individuals. A key metric for understanding blood glucose dynamics after eating is the postprandial area under the curve (PAUC). Predicting PAUC in advance based on a person's diet and activity level and explaining what affects postprandial blood glucose could allow an individual to adjust their lifestyle accordingly to maintain normal glucose levels. In this paper, we propose GlucoLens, an explainable machine learning approach to predict PAUC and hyperglycemia from diet, activity, and recent glucose patterns. We conducted a five-week user study with 10 full-time working individuals to develop and evaluate the computational model. Our machine learning model takes multimodal data including fasting glucose, recent glucose, recent activity, and macronutrient amounts, and provides an interpretable prediction of the postprandial glucose pattern. Our extensive analyses of the collected data revealed that the trained model achieves a normalized root mean squared error (NRMSE) of 0.123. On average, GlucoLense with a Random Forest backbone provides a 16% better result than the baseline models. Additionally, GlucoLens predicts hyperglycemia with an accuracy of 74% and recommends different options to help avoid hyperglycemia through diverse counterfactual explanations. Code available: https://github.com/ab9mamun/GlucoLens.

Type 1 Diabetes is a chronic autoimmune condition in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in little to no insulin production. Insulin helps glucose in your blood enter your muscle, fat, and liver cells so they can use it for energy or store it for later use. If insulin is insufficient, it causes sugar to build up in the blood and leads to serious health problems. People with Type 1 Diabetes need synthetic insulin every day. In diabetes management, continuous glucose monitoring is an important feature that provides near real-time blood glucose data. It is useful in deciding the synthetic insulin dose. In this research work, we used machine learning tools, deep neural networks, deep reinforcement learning, and voting and stacking regressors to predict blood glucose levels at 30-min time intervals using the latest DiaTrend dataset. Predicting blood glucose levels is useful in better diabetes management systems. The trained models were compared using several evaluation metrics. Our evaluation results demonstrate the performance of various models across different glycemic conditions for blood glucose prediction. The source codes of this work can be found in: https://github.com/soon-jynn-chu/t1d_bg_prediction

Accurately predicting blood glucose (BG) levels of ICU patients is critical, as both hypoglycemia (BG < 70 mg/dL) and hyperglycemia (BG > 180 mg/dL) are associated with increased morbidity and mortality. We develop the Multi-source Irregular Time-Series Transformer (MITST), a novel machine learning-based model to forecast the next BG level, classifying it into hypoglycemia, hyperglycemia, or euglycemia (70-180 mg/dL). The irregularity and complexity of Electronic Health Record (EHR) data, spanning multiple heterogeneous clinical sources like lab results, medications, and vital signs, pose significant challenges for prediction tasks. MITST addresses these using hierarchical Transformer architectures, which include a feature-level, a timestamp-level, and a source-level Transformer. This design captures fine-grained temporal dynamics and allows learning-based data integration instead of traditional predefined aggregation. In a large-scale evaluation using the eICU database (200,859 ICU stays across 208 hospitals), MITST achieves an average improvement of 1.7% (p < 0.001) in AUROC and 1.8% (p < 0.001) in AUPRC over a state-of-the-art baseline. For hypoglycemia, MITST achieves an AUROC of 0.915 and an AUPRC of 0.247, both significantly higher than the baseline's AUROC of 0.862 and AUPRC of 0.208 (p < 0.001). The flexible architecture of MITST allows seamless integration of new data sources without retraining the entire model, enhancing its adaptability in clinical decision support. Although this study focuses on predicting BG levels, MITST can easily be extended to other critical event prediction tasks in ICU settings, offering a robust solution for analyzing complex, multi-source, irregular time-series data.

Continuous glucose monitoring (CGM) devices provide real-time glucose monitoring and timely alerts for glycemic excursions, improving glycemic control among patients with diabetes. However, identifying rare events like hypoglycemia and hyperglycemia remain challenging due to their infrequency. Moreover, limited access to sensitive patient data hampers the development of robust machine learning models. Our objective is to accurately predict glycemic excursions while addressing data privacy concerns. To tackle excursion prediction, we propose a novel Hypo-Hyper (HH) loss function, which significantly improves performance in the glycemic excursion regions. The HH loss function demonstrates a 46% improvement over mean-squared error (MSE) loss across 125 patients. To address privacy concerns, we propose FedGlu, a machine learning model trained in a federated learning (FL) framework. FL allows collaborative learning without sharing sensitive data by training models locally and sharing only model parameters across other patients. FedGlu achieves a 35% superior glycemic excursion detection rate compared to local models. This improvement translates to enhanced performance in predicting both, hypoglycemia and hyperglycemia, for 105 out of 125 patients. These results underscore the effectiveness of the proposed HH loss function in augmenting the predictive capabilities of glucose predictions. Moreover, implementing models within a federated learning framework not only ensures better predictive capabilities but also safeguards sensitive data concurrently.

This paper presents a novel multi-agent reinforcement learning (RL) approach for personalized glucose control in individuals with type 1 diabetes (T1D). The method employs a closed-loop system consisting of a blood glucose (BG) metabolic model and a multi-agent soft actor-critic RL model acting as the basal-bolus advisor. Performance evaluation is conducted in three scenarios, comparing the RL agents to conventional therapy. Evaluation metrics include glucose levels (minimum, maximum, and mean), time spent in different BG ranges, and average daily bolus and basal insulin dosages. Results demonstrate that the RL-based basal-bolus advisor significantly improves glucose control, reducing glycemic variability and increasing time spent within the target range (70-180 mg/dL). Hypoglycemia events are effectively prevented, and severe hyperglycemia events are reduced. The RL approach also leads to a statistically significant reduction in average daily basal insulin dosage compared to conventional therapy. These findings highlight the effectiveness of the multi-agent RL approach in achieving better glucose control and mitigating the risk of severe hyperglycemia in individuals with T1D.

Significant advancements in type 1 diabetes treatment have been made in the development of state-of-the-art Artificial Pancreas Systems (APS). However, lapses currently exist in the timely treatment of unsafe blood glucose (BG) levels, especially in the case of rebound hyperglycemia. We propose a machine learning (ML) method for predictive BG scenario categorization that outputs messages alerting the patient to upcoming BG trends to allow for earlier, educated treatment. In addition to standard notifications of predicted hypoglycemia and hyperglycemia, we introduce BG scenario-specific alert messages and the preliminary steps toward precise basal suggestions for the prevention of rebound hyperglycemia. Experimental evaluation on the DCLP3 clinical dataset achieves >98% accuracy and >79% precision for predicting rebound high events for patient alerts.

Analyzing queries made to Google, Bing, and other search engines can reveal the potentially dangerous consequences of mixing prescriptions before they are known to the Food and Drug Administration (FDA), according to a new study. Such data mining could even expose medical risks that slip through clinical trials undetected. Pharmaceuticals often have side effects that go unnoticed until they're already available to the public. This is especially true of side effects that emerge when two drugs interact, largely because drug trials try to pinpoint the effects of one drug at a time. Physicians have a few ways to hunt for these hidden risks, such as reports to FDA from doctors, nurses, and patients.

Using data drawn from queries entered into Google, Microsoft and Yahoo search engines, scientists at Microsoft, Stanford and Columbia University have for the first time been able to detect evidence of unreported prescription drug side effects before they were found by the Food and Drug Administration's warning system. Using automated software tools to examine queries by six million Internet users taken from Web search logs in 2010, the researchers looked for searches relating to an antidepressant, paroxetine, and a cholesterol lowering drug, pravastatin. They were able to find evidence that the combination of the two drugs caused high blood sugar. The study, which was reported in the Journal of the American Medical Informatics Association on Wednesday, is based on data-mining techniques similar to those employed by services like Google Flu Trends, which has been used to give early warning of the prevalence of the sickness to the public. The F.D.A. asks physicians to report side effects through a system known as the Adverse Event Reporting System.

Diabetes management is a difficult task for patients, who must monitor and control their blood glucose levels in order to avoid serious diabetic complications. It is a difficult task for physicians, who must manually interpret large volumes of blood glucose data to tailor therapy to the needs of each patient. This paper describes three emerging applications that employ AI to ease this task and shares difficulties encountered in transitioning AI technology from university researchers to patients and physicians.